Beta Bionics, Inc. — a clinical stage medical technology company committed to the design, development, and commercialization of the iLet® Bionic Pancreas System — today announced the completion of a $57 million Series C equity financing. Proceeds from the financing will support product development, regulatory submissions, and preparations for the commercialization of the insulin dosing iLet® Bionic Pancreas System following FDA clearance. Click here to read more https://www.globenewswire.com/news-release/2022/02/17/2387549/0/en/Beta-Bionics-Announces-Closing-of-57-Million-Series-C-Financing.html